NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization394.33 mln
Float97.53 mln
Earnings Date08/06/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.18
Caution advised
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.08
Debt-free
ROE
-20.22
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
OmniAb is a California-based biotechnology company that licenses its antibody discovery technology to drug developers and research institutions across the United States, Europe, Asia, and Canada. The company uses a suite of specially engineered animals ? including modified rats, mice, chickens, and cattle ? whose immune systems have been designed to produce antibodies suitable for human medicines. These biological tools are supported by artificial intelligence and machine learning software to help partners find and refine the best possible drug candidates. Founded in 2012 and headquartered in Emeryville, OmniAb works with partners at every stage of early drug discovery to accelerate the development of new treatments.
